Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.
Basel, December 8, 2024 – Novartis today announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with Scemblix ® (asciminib) showing superior major molecular response ...
Basel, December 8, 2024 – Novartis today announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with Scemblix ® (asciminib) showing superior major molecular response (MMR) ...
Novartis (NVS) announced “positive,” longer-term results from the pivotal Phase 3 ASC4FIRST trial with Scemblix showing superior major molecular response rates at week 96. The study compared ...
Novartis announced positive, longer-term results from the pivotal phase III ASC4FIRST trial with Scemblix (asciminib) showing superior major molecular response (MMR) rates at week 961. The study ...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis's current product portfolio and pipeline are central to its growth strategy. Key products such as Cosentyx, Pluvicto, Kisqali, and Scemblix are expected to drive the company's mid-term ...
Prominent among these are Cosentyx, Pluvicto, Kisqali, and Scemblix. These products form the backbone of the company's near-term revenue strategy and are crucial for meeting its growth targets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback